AVEO Pharmaceuticals Inc. (AVEO) and Its Rivals Financial Results Comparison

As Biotechnology company, AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) is competing with its rivals based on the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Insider & Institutional Ownership

AVEO Pharmaceuticals Inc. has 31.9% of its shares held by institutional investors versus an average of 53.20% institutional ownership for its peers. On other hand AVEO Pharmaceuticals Inc. has 0.28% of its shares held by company insiders versus an average of 8.45% insiders ownership for its rivals.

Profitability

Table 1 has AVEO Pharmaceuticals Inc. and its rivals’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. 18,250,677,506.78% -11.10% 17.60%
Industry Average 812.10% 105.95% 28.39%

Earnings & Valuation

The following data compares AVEO Pharmaceuticals Inc. and its rivals’ gross revenue, net income and valuation.

Net Income Gross Revenue Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 134.69M 1 23.88
Industry Average 33.76M 4.16M 35.97

AVEO Pharmaceuticals Inc. has lower revenue and P/E Ratio than its peers. With presently lower price-to-earnings ratio AVEO Pharmaceuticals Inc. is more affordable than its rivals.

Analyst Ratings

Table 3 provides breakdown of recent ratings for AVEO Pharmaceuticals Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 0 1 3.00
Industry Average 1.10 1.78 2.38 2.81

AVEO Pharmaceuticals Inc. presently has a consensus target price of $1.75, suggesting a potential upside of 129.81%. The peers have a potential upside of 168.19%. AVEO Pharmaceuticals Inc.’s strong average rating and high probable upside, looks like is making equities research analysts believe that the business is more favorable than its rivals.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of AVEO Pharmaceuticals Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -10.03% -10.8% -31.77% -64.93% -70.3% -61.2%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year AVEO Pharmaceuticals Inc. has -61.20% weaker performance while AVEO Pharmaceuticals Inc.’s rivals have 54.83% stronger performance.

Liquidity

The Current Ratio and a Quick Ratio of AVEO Pharmaceuticals Inc. are 1.4 and 1.4. Competitively, AVEO Pharmaceuticals Inc.’s peers have 7.07 and 6.86 for Current and Quick Ratio. AVEO Pharmaceuticals Inc.’s competitors have better ability to pay short and long-term obligations than AVEO Pharmaceuticals Inc.

Volatility & Risk

AVEO Pharmaceuticals Inc. has a beta of 0.76 and its 24.00% less volatile than S&P 500. In other hand, AVEO Pharmaceuticals Inc.’s rivals have beta of 1.77 which is 76.75% more volatile than S&P 500.

Dividends

AVEO Pharmaceuticals Inc. does not pay a dividend.

Summary

AVEO Pharmaceuticals Inc.’s competitors beat on 6 of the 6 factors AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.